Sam Chun Dang Pharm. Co.,Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sam Chun Dang Pharm. Co.,Ltd
Takeda has inked three deals in recent days: a cancer antibody-drug conjugate partnership, a PI3K out-license and a nanomedicine drug-delivery pact. AstraZeneca gains expanded rights to Kyowa Hakko Kirin’s Fasenra.
South Korean biotech Alteogen is progressing the development of its Eylea biosimilar both at home and abroad, with the hope of becoming a global first mover with its version in wet AMD, backed by formulation and manufacturing patents.
Is there a new strategic Asian pharma partnership in the works? Early days perhaps but worth keeping an eye on the India-South Korea deal street.
AstraZeneca takes second license of antisense candidate under 2012 pact with Ionis, this time for kidney disease. Aldeyra is working with J&J on novel immune-modulating drugs for systemic inflammatory conditions.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Sam Chun Dang Pharm Co Ltd.